Loading…
Reported covered position: Chief of staff to Rep. Xavier Becerra, legislative director to Rep. Becerra, legislative counsel to Rep. Becerra, chief of staff, Office of Policy and Planning, U.S. Department of Education, Immigration Counsel, U.S. Department of Justice.
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
National Defense Authorization Act for Fiscal Year 2026
Client: VIATRIS INC · Firm: FEROX STRATEGIES
Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations and National Defense Authorization Act (S. 1071).
National Defense Authorization Act for Fiscal Year 2026
Client: VIATRIS INC · Firm: FEROX STRATEGIES
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
VIATRIS INC via FEROX STRATEGIES
2026 · third_quarter · Q3
Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations and National Defense Authorization Act (S. 1071).
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
TELEVISAUNIVISION, INC. via FEROX STRATEGIES
2026 · third_quarter · Q3
Source: Senate LDA
| AVIDITY BIOSCIENCES, INC. |
| 15 |
| 2023–2026 |
| ZEBRA TECHNOLOGIES CORPORATION | 14 | 2022–2025 |
| DLA PIPER LLP (US) ON BEHALF OF ILLUMINA, INC. | 8 | 2021–2023 |
| ADTALEM GLOBAL EDUCATION | 7 | 2025–2026 |
| DATAROBOT INC | 7 | 2021–2022 |
| RARE DISEASE COMPANY COALITION | 7 | 2025–2026 |
| MICROSOFT CORPORATION | 5 | 2021 |
| NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION (NEMA) | 5 | 2025–2026 |
| ASSOCIATION FOR ACCESSIBLE MEDICINES | 4 | 2026 |
| ATRIUM THERAPEUTICS | 4 | 2026 |
| SELF-INSURANCE INSTITUTE OF AMERICA, INC. | 4 | 2022 |
| AGE IN PLACE | 3 | 2026 |
| Fresenius Kabi USA, LLC | 3 | 2026 |
| THE GAP INC. | 3 | 2021 |
| WESTFIELD LLC | 3 | 2021 |
| DECISION SCIENCES INTERNATIONAL CORP | 2 | 2026 |
| NEURELIS, INC. | 2 | 2026 |
| PALANTIR TECHNOLOGIES, INC. | 2 | 2026 |
| THE ERISA INDUSTRY COMMITTEE (ERIC) | 2 | 2026 |
| EQUINOX INTERNATIONAL SAC | 1 | 2021 |
| NATIONAL FOOTBALL LEAGUE | 1 | 2026 |
| STOKE THERAPEUTICS | 1 | 2026 |
| SURGENEX | 1 | 2026 |
| WORKDAY, INC. | 1 | 2026 |
Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations and National Defense Authorization Act (S. 1071).
National Defense Authorization Act for Fiscal Year 2026
Client: VIATRIS INC · Firm: FEROX STRATEGIES
Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations and National Defense Authorization Act (S. 1071).
Issues related to rare disease pharmaceuticals, Orphan Cures H.R. 946, and Pediatric Priority Review Voucher.
Issues related to rare disease pharmaceuticals, Orphan Cures H.R. 946, and Pediatric Priority Review Voucher.
Issues related to rare disease pharmaceuticals, Orphan Cures H.R. 946, and Pediatric Priority Review Voucher.
Issues related to rare disease pharmaceuticals, Orphan Cures H.R. 946, and Pediatric Priority Review Voucher.
National Defense Authorization Act for Fiscal Year 2026
Client: VIATRIS INC · Firm: FEROX STRATEGIES
Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations and National Defense Authorization Act (S. 1071).
Issues related to the pharmaceutical industry. (H.R.1577 and S. 596) - Treat and Reduce Obesity Act of 2021.
Issues related to the pharmaceutical industry. (H.R.1577 and S. 596) - Treat and Reduce Obesity Act of 2021.
Issues related to the pharmaceutical industry. (H.R.1577 and S. 596) - Treat and Reduce Obesity Act of 2021.
Issues related to the pharmaceutical industry. (H.R.1577 and S. 596) - Treat and Reduce Obesity Act of 2021.
Restore Protections for Dialysis Patients Act
Client: SELF-INSURANCE INSTITUTE OF AMERICA, INC. · Firm: FEROX STRATEGIES
General issues related to the Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750).
Restore Protections for Dialysis Patients Act
Client: SELF-INSURANCE INSTITUTE OF AMERICA, INC. · Firm: FEROX STRATEGIES
General issues related to the Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750).
Restore Protections for Dialysis Patients Act
Client: SELF-INSURANCE INSTITUTE OF AMERICA, INC. · Firm: FEROX STRATEGIES
General issues related to the Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750).
Restore Protections for Dialysis Patients Act
Client: SELF-INSURANCE INSTITUTE OF AMERICA, INC. · Firm: FEROX STRATEGIES
General issues related to the Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750).
Restore Protections for Dialysis Patients Act
Client: SELF-INSURANCE INSTITUTE OF AMERICA, INC. · Firm: FEROX STRATEGIES
General issues related to the Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750).
Restore Protections for Dialysis Patients Act
Client: SELF-INSURANCE INSTITUTE OF AMERICA, INC. · Firm: FEROX STRATEGIES
General issues related to the Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750).
Restore Protections for Dialysis Patients Act
Client: SELF-INSURANCE INSTITUTE OF AMERICA, INC. · Firm: FEROX STRATEGIES
General issues related to the Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750).
Restore Protections for Dialysis Patients Act
Client: SELF-INSURANCE INSTITUTE OF AMERICA, INC. · Firm: FEROX STRATEGIES
General issues related to the Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750).
Issues related to the pharmaceutical industry. (H.R.1577 and S. 596) - Treat and Reduce Obesity Act of 2021.
Issues related to the pharmaceutical industry. (H.R.1577 and S. 596) - Treat and Reduce Obesity Act of 2021.
Issues related to the pharmaceutical industry. (H.R.1577 and S. 596) - Treat and Reduce Obesity Act of 2021.
Issues related to the pharmaceutical industry. (H.R.1577 and S. 596) - Treat and Reduce Obesity Act of 2021.
Issues related to the pharmaceutical industry. (H.R.1577 and S. 596) - Treat and Reduce Obesity Act of 2021.
Issues related to the pharmaceutical industry. (H.R.1577 and S. 596) - Treat and Reduce Obesity Act of 2021.
H.R.840 - Retail Revitalization Act. General issues related to taxation of real estate investment trusts (REITs).
Corporate tax issues. Issues related to COVID-19 relief. H.R.840 - Retail Revitalization Act. General issues related to taxation of real estate investment trusts (REITs).
H.R.840 - Retail Revitalization Act. General issues related to taxation of real estate investment trusts (REITs). Tax issues related to reconciliation legislation.
Issues related to the pharmaceutical industry. (H.R.1577 and S. 596) - Treat and Reduce Obesity Act of 2021.
Issues related to the pharmaceutical industry. (H.R.1577 and S. 596) - Treat and Reduce Obesity Act of 2021.
General issues related to telecommunications.
General issues related to appropriations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
General issues related to skin substitutes.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
STOKE THERAPEUTICS via FEROX STRATEGIES
2026 · third_quarter · Q3
General issues related to rare disease treatment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RARE DISEASE COMPANY COALITION via FEROX STRATEGIES
2026 · third_quarter · Q3
General issues related to rare disease treatment development.
General issues related to rare disease treatment.
General issues related to tariffs.
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
NEURELIS, INC. via FEROX STRATEGIES
2026 · third_quarter · Q3
General issues related to epilepsy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION (NEMA) via FEROX STRATEGIES
2026 · third_quarter · Q3
General issues related to radiopharmaceuticals.
General issues related to radiopharmaceutical tariffs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE
FRESENIUS KABI USA LLC via FEROX STRATEGIES
2026 · third_quarter · Q3
General issues related to trade.
General healthcare issues related to biosimilar industries.
General patent issues related to biosimilar industries.
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
THE ERISA INDUSTRY COMMITTEE (ERIC) via FEROX STRATEGIES
2026 · third_quarter · Q3
General issues related to employer sponsored health plans.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via FEROX STRATEGIES
2026 · third_quarter · Q3
Issues related to the pharmaceutical industry. Issues related to treating and reducing obesity. Issues related to drug shortages and counterfeit products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVIDITY BIOSCIENCES, INC. via FEROX STRATEGIES
2026 · third_quarter · 3T
Issues related to rare disease pharmaceuticals, and general FDA reforms related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ATRIUM THERAPEUTICS via FEROX STRATEGIES
2026 · third_quarter · Q3
General issues related to rare disease pharmaceuticals, and general FDA reforms related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALEXION PHARMACEUTICALS, INC. via FEROX STRATEGIES
2026 · third_quarter · Q3
General issues related to the rare disease pharmaceutical ecosystem.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION FOR ACCESSIBLE MEDICINES via FEROX STRATEGIES
2026 · third_quarter · Q3
General issues related to generic development and commercialization.
General issues related to trade.
General issues related to treatment access.
WORKDAY, INC. via FEROX STRATEGIES
2026 · third_quarter · RR
Educate policymakers about Workdays cutting edge human resources, finance and AI cloud software.
Educate policymakers about Workdays cutting edge human resources, finance and AI cloud software.
NEURELIS, INC. via FEROX STRATEGIES
2026 · third_quarter · RR
General issues related to federal regulation of the healthcare industry.
General issues related to federal regulation of the healthcare industry.
THE ERISA INDUSTRY COMMITTEE (ERIC) via FEROX STRATEGIES
2026 · third_quarter · RR
General issues related to employee sponsored health insurance.
General issues related to employee sponsored health insurance.
VIATRIS INC via FEROX STRATEGIES
2026 · second_quarter · Q2
Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations and National Defense Authorization Act (S. 1071).
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
TELEVISAUNIVISION, INC. via FEROX STRATEGIES
2026 · second_quarter · Q2
General issues related to appropriations.
General issues related to telecommunications.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RARE DISEASE COMPANY COALITION via FEROX STRATEGIES
2026 · second_quarter · Q2
General issues related to tariffs.
General issues related to rare disease treatment.
General issues related to rare disease treatment development.
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
NATIONAL FOOTBALL LEAGUE via FEROX STRATEGIES
2026 · second_quarter · Q2
Issues related to the impact of tax legislation on sports leagues.
Issues related to broadcast policies, IP protection, and federal ticket reforms.
Issues relating to stadium security, franchise, federal regulation of sports betting, and drone safety.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION (NEMA) via FEROX STRATEGIES
2026 · second_quarter · Q2
General issues related to radiopharmaceutical tariffs.
General issues related to radiopharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FRESENIUS KABI USA LLC via FEROX STRATEGIES
2026 · second_quarter · Q2
General issues related to trade.
General healthcare issues related to biosimilar industries.
General patent issues related to biosimilar industries.
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via FEROX STRATEGIES
2026 · second_quarter · Q2
Issues related to the pharmaceutical industry. Issues related to treating and reducing obesity. Issues related to drug shortages and counterfeit products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DECISION SCIENCES INTERNATIONAL CORP via FEROX STRATEGIES
2026 · second_quarter · Q2
General issues related to Homeland Appropriations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COVISTA (FORMERLY KNOWN AS ADTALEM GLOBAL EDUCATION) via FEROX STRATEGIES
2026 · second_quarter · 2T
General issues related to for-profit higher education.
General issues related to for-profit higher education.
General issues related to for-profit higher education.
COVISTA (FORMERLY KNOWN AS ADTALEM GLOBAL EDUCATION) via FEROX STRATEGIES
2026 · second_quarter · Q2
General issues related to for-profit higher education.
General issues related to for-profit higher education.
General issues related to for-profit higher education.
AVIDITY BIOSCIENCES, INC. via FEROX STRATEGIES
2026 · second_quarter · Q2
Issues related to rare disease pharmaceuticals, and general FDA reforms related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ATRIUM THERAPEUTICS via FEROX STRATEGIES
2026 · second_quarter · Q2
General issues related to rare disease pharmaceuticals, and general FDA reforms related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALEXION PHARMACEUTICALS, INC. via FEROX STRATEGIES
2026 · second_quarter · Q2
General issues related to the rare disease pharmaceutical ecosystem.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AGE IN PLACE via FEROX STRATEGIES
2026 · second_quarter · Q2
General issues related to digital health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
ASSOCIATION FOR ACCESSIBLE MEDICINES via FEROX STRATEGIES
2026 · second_quarter · Q2
General issues related to generic development and commercialization.
General issues related to treatment access.
General issues related to patents and access to generics/biosimilars.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIATRIS INC via FEROX STRATEGIES
2026 · first_quarter · Q1
Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations and National Defense Authorization Act (S. 1071).
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
TELEVISAUNIVISION, INC. via FEROX STRATEGIES
2026 · first_quarter · Q1
General issues related to appropriations.
General issues related to telecommunications.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RARE DISEASE COMPANY COALITION via FEROX STRATEGIES
2026 · first_quarter · Q1
General issues related to tariffs.
General issues related to rare disease treatment.
General issues related to rare disease treatment development.
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PALANTIR TECHNOLOGIES, INC. via FEROX STRATEGIES
2026 · first_quarter · Q1
Educate policymakers about security and data privacy.
Educate policymakers about security and data privacy.
Educate policymakers about security and data privacy.
NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION (NEMA) via FEROX STRATEGIES
2026 · first_quarter · Q1
General issues related to radiopharmaceutical tariffs.
General issues related to radiopharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FRESENIUS KABI USA LLC via FEROX STRATEGIES
2026 · first_quarter · Q1
General healthcare issues related to biosimilar industries.
General patent issues related to biosimilar industries.
General issues related to trade.
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via FEROX STRATEGIES
2026 · first_quarter · Q1
Issues related to the pharmaceutical industry. Issues related to treating and reducing obesity. Issues related to drug shortages and counterfeit products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DECISION SCIENCES INTERNATIONAL CORP via FEROX STRATEGIES
2026 · first_quarter · Q1
General issues related to Homeland Appropriations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COVISTA (FORMERLY KNOWN AS ADTALEM GLOBAL EDUCATION) via FEROX STRATEGIES
2026 · first_quarter · Q1
General issues related to for-profit higher education.
General issues related to for-profit higher education.
General issues related to for-profit higher education.
AVIDITY BIOSCIENCES, INC. via FEROX STRATEGIES
2026 · first_quarter · Q1
Issues related to rare disease pharmaceuticals, and general FDA reforms related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ATRIUM THERAPEUTICS via FEROX STRATEGIES
2026 · first_quarter · Q1
General issues related to rare disease pharmaceuticals, and general FDA reforms related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALEXION PHARMACEUTICALS, INC. via FEROX STRATEGIES
2026 · first_quarter · Q1
Issues related to rare disease pharmaceuticals, ORPHAN Cures, and Pediatric Priority Review Voucher
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AGE IN PLACE via FEROX STRATEGIES
2026 · first_quarter · Q1
General issues related to digital health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
ASSOCIATION FOR ACCESSIBLE MEDICINES via FEROX STRATEGIES
2026 · first_quarter · Q1
General issues related to generic development and commercialization.
General issues related to treatment access.
General issues related to patents and access to generics/biosimilars.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AGE IN PLACE via FEROX STRATEGIES
2026 · first_quarter · RR
General issues related to digital health.
ASSOCIATION FOR ACCESSIBLE MEDICINES via FEROX STRATEGIES
2026 · first_quarter · RR
General issues related to generic and biosimilar drug development.
General issues related to generic and biosimilar drug development.
General issues related to generic and biosimilar drug development.
ATRIUM THERAPEUTICS via FEROX STRATEGIES
2026 · first_quarter · RR
General issues related to rare disease pharmaceuticals.
General issues related to rare disease pharmaceuticals.
PALANTIR TECHNOLOGIES, INC. via FEROX STRATEGIES
2026 · first_quarter · RR
General issues related to data analytics and technology.
General issues related to data analytics and technology.
General issues related to data analytics and technology.
VIATRIS INC via FEROX STRATEGIES
2025 · fourth_quarter · Q4
Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations and National Defense Authorization Act (S. 1071).
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
SEASONAL EMPLOYMENT ALLIANCE via FEROX STRATEGIES
2025 · fourth_quarter · 4T
General work related to the H-2B program.
General issues related to H-2B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RARE DISEASE COMPANY COALITION via FEROX STRATEGIES
2025 · fourth_quarter · Q4
General issues related to rare disease treatment development.
General issues related to rare disease treatment.
General issues related to tariffs.
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION (NEMA) via FEROX STRATEGIES
2025 · fourth_quarter · Q4
General issues related to radiopharmaceuticals.
General issues related to radiopharmaceutical tariffs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via FEROX STRATEGIES
2025 · fourth_quarter · Q4
Issues related to the pharmaceutical industry. Issues related to treating and reducing obesity. Issues related to drug shortages and counterfeit products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVIDITY BIOSCIENCES, INC. via FEROX STRATEGIES
2025 · fourth_quarter · Q4
Issues related to rare disease pharmaceuticals, and general FDA reforms related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALEXION PHARMACEUTICALS, INC. via FEROX STRATEGIES
2025 · fourth_quarter · Q4
Issues related to rare disease pharmaceuticals, Orphan Cures H.R. 946, and Pediatric Priority Review Voucher.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COVISTA (FORMERLY KNOWN AS ADTALEM GLOBAL EDUCATION) via FEROX STRATEGIES
2025 · fourth_quarter · Q4
General issues related to for-profit higher education.
General issues related to for-profit higher education.
General issues related to for-profit higher education.
SEASONAL EMPLOYMENT ALLIANCE via FEROX STRATEGIES
2025 · third_quarter · Q3
General work related to the H-2B program.
General issues related to H-2B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RARE DISEASE COMPANY COALITION via FEROX STRATEGIES
2025 · third_quarter · Q3
General issues related to rare disease treatment development.
General issues related to rare disease treatment.
General issues related to tariffs.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
RAI SERVICES COMPANY (FORMERLY KNOWN AS REYNOLDS AMERICAN) via FEROX STRATEGIES
2025 · third_quarter · Q3
General issues related to the tobacco industry.
Issues related to illicit trade.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via FEROX STRATEGIES
2025 · third_quarter · Q3
Issues related to the pharmaceutical industry. Issues related to treating and reducing obesity. Issues related to drug shortages and counterfeit products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVIDITY BIOSCIENCES, INC. via FEROX STRATEGIES
2025 · third_quarter · Q3
Issues related to rare disease pharmaceuticals, and general FDA reforms related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALEXION PHARMACEUTICALS, INC. via FEROX STRATEGIES
2025 · third_quarter · Q3
Issues related to rare disease pharmaceuticals, Orphan Cures H.R. 946, and Pediatric Priority Review Voucher.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COVISTA (FORMERLY KNOWN AS ADTALEM GLOBAL EDUCATION) via FEROX STRATEGIES
2025 · third_quarter · Q3
General issues related to for-profit higher education.
General issues related to for-profit higher education.
General issues related to for-profit higher education.
NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION (NEMA) via FEROX STRATEGIES
2025 · fourth_quarter · RR
General issues related to medical imaging and radio-pharmaceuticals.
General issues related to medical imaging and radio-pharmaceuticals.
VIATRIS INC via FEROX STRATEGIES
2025 · third_quarter · Q3
Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations.
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
RARE DISEASE COMPANY COALITION via FEROX STRATEGIES
2025 · second_quarter · Q2
General issues related to rare disease treatment development.
General issues related to rare disease treatment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SEASONAL EMPLOYMENT ALLIANCE via FEROX STRATEGIES
2025 · second_quarter · Q2
General work related to the H-2B program.
General issues related to H-2B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RAI SERVICES COMPANY (FORMERLY KNOWN AS REYNOLDS AMERICAN) via FEROX STRATEGIES
2025 · second_quarter · Q2
General issues related to the tobacco industry.
Issues related to illicit trade.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVIDITY BIOSCIENCES, INC. via FEROX STRATEGIES
2025 · second_quarter · Q2
Issues related to rare disease pharmaceuticals, and general FDA reforms related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COVISTA (FORMERLY KNOWN AS ADTALEM GLOBAL EDUCATION) via FEROX STRATEGIES
2025 · second_quarter · Q2
General issues related to for-profit higher education.
General issues related to for-profit higher education.
General issues related to for-profit higher education.
VIATRIS INC via FEROX STRATEGIES
2025 · second_quarter · Q2
Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations.
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via FEROX STRATEGIES
2025 · second_quarter · Q2
Issues related to the pharmaceutical industry. Issues related to Treating and Reducing Obesity.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALEXION PHARMACEUTICALS, INC. via FEROX STRATEGIES
2025 · second_quarter · Q2
Issues related to rare disease pharmaceuticals, Orphan Cures H.R. 946, and Pediatric Priority Review Voucher.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COVISTA (FORMERLY KNOWN AS ADTALEM GLOBAL EDUCATION) via FEROX STRATEGIES
2025 · second_quarter · RR
General issues related to higher education.
General issues related to higher education.
General issues related to higher education.
RARE DISEASE COMPANY COALITION via FEROX STRATEGIES
2025 · second_quarter · RR
Scientific research and education
Scientific research and education
Scientific research and education
ZEBRA TECHNOLOGIES CORPORATION via FEROX STRATEGIES
2025 · first_quarter · 1T
General issues related to supply chain management and IT modernization.
General issues related to supply chain management and IT modernization.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIATRIS INC via FEROX STRATEGIES
2025 · first_quarter · Q1
Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SEASONAL EMPLOYMENT ALLIANCE via FEROX STRATEGIES
2025 · first_quarter · Q1
General work related to the H-2B program.
General issues related to H-2B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RAI SERVICES COMPANY (FORMERLY KNOWN AS REYNOLDS AMERICAN) via FEROX STRATEGIES
2025 · first_quarter · Q1
General issues related to the tobacco industry.
Issues related to illicit trade.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via FEROX STRATEGIES
2025 · first_quarter · Q1
Issues related to the pharmaceutical industry. Issues related to Treating and Reducing Obesity.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVIDITY BIOSCIENCES, INC. via FEROX STRATEGIES
2025 · first_quarter · Q1
Issues related to rare disease pharmaceuticals, and general FDA reforms related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALEXION PHARMACEUTICALS, INC. via FEROX STRATEGIES
2025 · first_quarter · Q1
Issues related to rare disease pharmaceuticals, Orphan Cures H.R. 946, and Pediatric Priority Review Voucher.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TELEVISAUNIVISION, INC. via FEROX STRATEGIES
2024 · fourth_quarter · Q4
Issues related to FY25 Appropriations in regard to limited English proficient communities.
General issues related to telecommunications and data privacy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZEBRA TECHNOLOGIES CORPORATION via FEROX STRATEGIES
2024 · fourth_quarter · Q4
General issues related to supply chain management and IT modernization.
General issues related to supply chain management and IT modernization.
General issues related to supply chain management and IT modernization.
VIATRIS INC via FEROX STRATEGIES
2024 · fourth_quarter · Q4
Policy and oversight related to the generic pharmaceutical industry; Issues related to drug pricing; Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SEASONAL EMPLOYMENT ALLIANCE via FEROX STRATEGIES
2024 · fourth_quarter · Q4
General work related to the H-2B program.
General issues related to H-2B program.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Labor, Dept of (DOL), SENATE
RAI SERVICES COMPANY (FORMERLY KNOWN AS REYNOLDS AMERICAN) via FEROX STRATEGIES
2024 · fourth_quarter · Q4
Issues related to illicit trade.
General issues related to the tobacco industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via FEROX STRATEGIES
2024 · fourth_quarter · Q4
Issues related to the pharmaceutical industry; Issues related to Treating and Reducing Obesity.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AVIDITY BIOSCIENCES, INC. via FEROX STRATEGIES
2024 · fourth_quarter · Q4
General issues related to FY25 Agriculture/FDA Appropriations.
Issues related to rare disease pharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALEXION PHARMACEUTICALS, INC. via FEROX STRATEGIES
2024 · fourth_quarter · Q4
Issues related to rare disease pharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ZEBRA TECHNOLOGIES CORPORATION via FEROX STRATEGIES
2024 · third_quarter · Q3
General issues related to FY25 DOD Appropriations
General issues related to supply chain, vaccine safety and IT modernization.
General issues related to supply chain, vaccine safety and IT modernization.
VIATRIS INC via FEROX STRATEGIES
2024 · third_quarter · Q3
Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TELEVISAUNIVISION, INC. via FEROX STRATEGIES
2024 · third_quarter · Q3
Issues related to FY24 Appropriations in regard to limited English proficient communities.
General issues related to telecommunications and data privacy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SEASONAL EMPLOYMENT ALLIANCE via FEROX STRATEGIES
2024 · third_quarter · Q3
General work related to the H-2B program.
General issues related to H-2B program.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Labor, Dept of (DOL), SENATE
RAI SERVICES COMPANY (FORMERLY KNOWN AS REYNOLDS AMERICAN) via FEROX STRATEGIES
2024 · third_quarter · Q3
General issues related to the tobacco industry.
Issues related to illicit trade.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via FEROX STRATEGIES
2024 · third_quarter · Q3
Issues related to the pharmaceutical industry; Issues related to Treating and Reducing Obesity.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AVIDITY BIOSCIENCES, INC. via FEROX STRATEGIES
2024 · third_quarter · Q3
General issues related to FY25 Agriculture/FDA Appropriations.
Issues related to rare disease pharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALEXION PHARMACEUTICALS, INC. via FEROX STRATEGIES
2024 · third_quarter · Q3
Issue related to rare disease pharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
General issues related to patents and access to generics/biosimilars.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General issues related to for-profit higher education.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General issues related to for-profit higher education.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Educate policymakers about security and data privacy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General issues related to for-profit higher education.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General issues related to data analytics and technology.
General issues related to data analytics and technology.
General issues related to for-profit higher education.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General issues related to for-profit higher education.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General issues related to for-profit higher education.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General issues related to higher education.
Scientific research and education
General issues related to FY25 DOD Appropriations
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Transportation, Dept of (DOT)
General issues related to supply chain, vaccine safety and IT modernization.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Transportation, Dept of (DOT)